Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESRIX-III: Allogeneic Stem Cells for Radiation-Induced Xerostomia
NCT04776538Phase 2Unknown
- Sponsor
- Rigshospitalet
- Start
- Feb 2021
- Primary completion
- Mar 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of Adipose-derived allogeneic mesenchymal stem cells (IIS-FJD) in radiation-induced hyposalivation (RIX), xerostomia, sponsored by Rigshospitalet. Status: unknown.
02
Drugs
Adipose-derived allogeneic mesenchymal stem cells (IIS-FJD)
03
Conditions
radiation-induced hyposalivation (RIX)xerostomia
Beyond the preview
Go deeper on NCT04776538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776538.